article thumbnail

Gilead’s Vemlidy expands label to treat paediatric chronic HBV

Pharmaceutical Technology

Vemlidy was first approved to treat adults with HBV in 2016. Its label was expanded in 2022 for use in patients 12 years and older.

article thumbnail

Could Ozempic prevent heart attack and stroke?

The Checkup by Singlecare

Ozempic has also shown promise as a weight-loss medication and is often prescribed off-label for this purpose. For example, the 2016 SUSTAIN-6 trial tested the cardiovascular safety of semaglutide in patients with Type 2 diabetes who had established cardiovascular diseases or were at high risk.

FDA 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Top 10 Journal Articles To Read During Your Infectious Diseases Pharmacy Rotation

IDStewardship

It’s from 2016 about the future of antibiotics and resistance, but it remains highly relevant today and people consistently give positive feedback about it. ” Labeling the use of an antibiotic as inappropriate or appropriate cannot simply be done based upon whether it is FDA-approved for a given indication.

article thumbnail

Apple adds medication tracking to iPhone and Apple Watch

pharmaphorum

The new tool works as a component of Apple’s Health app and will let users add drugs or other health products like vitamins and supplements to a personal list – either by scanning a label or finding the product in a directory – and create custom schedules for them.

article thumbnail

Merck partners neuroloop on bioelectronic device for inflammation

pharmaphorum

neuroloop – a spinout of Freiburg University in Germany formed in 2016 – has been working to date on using its device as an implant to lower blood pressure, among other applications. The Merck collaboration will concentrate on using the device alongside anti-inflammatory drug therapies.

article thumbnail

Bayer unit BrainVectis cleared to start Huntington gene therapy trial

pharmaphorum

The phase 1/2 trial will be an open-label, dose-escalation study that will test various doses of BV-101 in between 12 and 18 subjects. In 2019, Bayer bought cell therapy company BlueRock Therapeutics, which was created in 2016 via a joint venture between Bayer and Versant Ventures.

Labelling 105
article thumbnail

Smartphone-powered trial backs J&J’s Invokana for heart failure

pharmaphorum

Updated labelling for Invokana has already been approved to include data showing that it can reduce the risk of hospitalisation for heart failure and diabetic kidney disease in patients with type 2 diabetes, based on the CREDENCE trial. . billion in 2016 before the product was linked to an increased risk of lower limb amputation.

Labelling 105